Fairmount Funds Management LLC
Long book
$1.38B
Q1 2026
Positions
12
Top-10 weight
97%
concentration
Last quarter
+30.9%
SPY +14.8%
Turnover
21%
of book per quarter
Strategy in plain words
auto-generated from filingsFairmount Funds Management LLC is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $1.38B US long book across 12 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: DAMORA THERAPEUTICS INC, DIANTHUS THERAPEUTICS INC, COGENT BIOSCIENCES INC, SPYRE THERAPEUTICS INC, ORUKA THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 9.6pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-5.3%
Q2 2024
+25.1%
Q3 2024
-19.3%
Q4 2024
-11.5%
Q1 2025
+4.2%
Q2 2025
+28.5%
Q3 2025
+51.0%
Q4 2025
+22.9%
Q1 2026
+30.9%
Sector allocation
Healthcare 100%
Long book by quarter
What does Fairmount Funds own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| DMRA DAMORA THERAPEUTICS INC | Healthcare | 8.7M | $225.7M | 16.3% | New |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 2.5M | $212.9M | 15.4% | +18.7% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 5.5M | $211.8M | 15.3% | -38.9% |
| SYRE SPYRE THERAPEUTICS INC | Healthcare | 4.0M | $202.7M | 14.6% | Held |
| ORKA ORUKA THERAPEUTICS INC | Healthcare | 3.7M | $181.7M | 13.1% | Held |
| VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 3.9M | $76.6M | 5.5% | Held |
| ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 1.9M | $72.7M | 5.3% | -50.0% |
| JBIO JADE BIOSCIENCES INC | Healthcare | 4.6M | $64.0M | 4.6% | Held |
| CBIO CRESCENT BIOPHARMA INC | Healthcare | 2.7M | $50.5M | 3.6% | Held |
| ZBIO ZENAS BIOPHARMA INC | Healthcare | 2.4M | $46.1M | 3.3% | +6.8% |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 298.6K | $25.1M | 1.8% | -85.4% |
| IKT INHIBIKASE THERAPEUTICS INC | Healthcare | 8.6M | $14.5M | 1.0% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 12 | $1.38B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 13 | $1.31B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 17 | $1.11B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 17 | $771.9M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 15 | $644.6M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 17 | $1.01B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 15 | $1.23B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 13 | $885.1M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 15 | $917.4M | canonical | SEC ↗ |